Vioxx and Bextra Lawsuits Could Tie Up Courts for Years
In September, 2004, pharmaceutical giant Merck voluntarily withdrew its painkilling medication Vioxx from the market. Studies show that Vioxx increases the risk of heart attack and stroke among patients who have used the drug for longer than 18 months. Vioxx, a drug from a family of non-steroidal anti-inflammatory drugs known as COX-2 inhibitors, is one of only a few drugs specifically designed to minimize inflammation while avoiding the stomach disorders long associated with other anti-inflammatory medications. Since its introduction in 1999, Vioxx has been a huge success, and sales of the drug worldwide topped $2.5 billion in 2003. That is certainly a great deal of money, but it pales when compared to the amount that Merck stands to lose through product liability lawsuits, which will soon come to court. As of this writing, several thousand lawsuits have been filed nationally, but attorneys estimate that the total number of lawsuits filed could reach a staggering 100,000.
One hundred thousand lawsuits is certainly a formidable number, but that figure could represent only half of the number of lawsuits related to COX-2 inhibitors. Earlier this year, Pfizer voluntarily withdrew its similar medication Bextra from the market, as studies linked the use of Bextra to increased heart attack risk and to a rare skin disorder known as Stevens-Johnson Syndrome. Bextra, another drug in the family of COX-2 inhibitors, works very similarly to Vioxx, and many patients who formerly took Vioxx switched to Bextra after the former was removed from the market last fall. Given that sales of Bextra rose to near Vioxx levels before it was removed from the market, it seems likely that the number of lawsuits filed by patients who claim to have been harmed by their use of Bextra could eventually equal the number of Vioxx lawsuits.
Unless the courts consolidate them into just a few class-action suits, the 200,000 potential lawsuits stemming from problems with Bextra and Vioxx could cripple our courts for the next decade. Patients who believe that they may have been harmed through the use of either Bextra or Vioxx would be well advised to contact an attorney who specializes in pharmaceutical lawsuits as soon as possible. The wait for a resolution in court, particularly for Vioxx lawsuits, could be a very long one. Those who file quickly may get the fastest results.
©Copyright 2005 by Retro Marketing.
Charles Essmeier is the owner of Retro Marketing, a firm devoted to informational Websites, including Bextra-Info.net, a site devoted to the withdrawn drug Bextra and StructuredSettlementHelp.com, a site devoted to structured settlements.
Latest News
BioImagene CEO, Dr. Ajit Singh, Speaks On Enabling Personalized ... MarketWatch - Digital pathology, a key enabler for personalized medicine, will aid clinicians in managing and interpreting data from a whole new set of diagnostic tests ... Aperio Introduces SecondSlide(TM) Digital Slide Sharing Network |
 SmartAboutHealth | Medicine for the Job Market New York Times, United States - By JONATHAN GRUBER A CENTRAL feature of Barack Obama’s presidential campaign was an aggressive plan to expand health insurance coverage by subsidizing ... Reform or bust New Report Shows Slower Premium Growth, But Increasing Pressure to ... Health Corps |
 eFluxMedia | American College of Surgeons Comments on Institute of Medicine ... MarketWatch - CHICAGO, Dec 03, 2008 /PRNewswire-USNewswire via COMTEX/ -- The American College of Surgeons (ACS) today recognized the Institute of Medicine (IOM) for its ... Report urges more sleep for medical residents Medical Residents Must Sleep After 16 Hours, Experts Urge Expert Panel Seeks Changes in Training of Medical Residents |
Research and Markets: 2008 Integrative Medicine and Dietary ... MarketWatch - In this 32-page issue, we offer a breakdown of 2007 US Complementary and Alternative Medicine sales data and provides a detailed analysis of new integrative ... |
 Afrik.com | 34 Nigerian Children Dead From Tainted Medicine Voice of America - By VOA News Nigerian health officials say they are flying in doses of an antidote for a poisoned teething medicine that has now killed 34 infants. ... 'Toxic' syrup kills Nigerian babies Teething mixture kills more Nigerian babies Nigeria infant drug toll hits 34, antidote flown in |
Research database from the US Library of Medicine The Plain Dealer - cleveland.com, OH - Search PubMed, Clinicaltrials.gov, the CDC and a dozen other medical sites - all at once. AP MEDICAL VIDEO by Michael O'Malley and Joan Mazzolini/Plain ... |
A New Index of Preventive Medicine Companies Motley Fool - The accompanying table [click to enlarge] presents statistics and the top 15 rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. ... |
NIGERIA: Jos displaced grapple with food, water, medicine shortages IRINnews.org, NY - JOS, 4 December 2008 (IRIN) - Water, medicine and food supplies are running low for an estimated 10000 people displaced by violence in Jos, northern Nigeria ... |
 Canada.com | "Rogue" stem cell clinics exploit hope: report Reuters - "The direct-to-consumer portrayal of stem cell medicine is optimistic and unsupported by published evidence," Timothy Caulfield of the University of Alberta ... Scientists warn of “rogue” online stem cell clinics Internet stem-cell clinics 'exploiting' MS and Parkinson's patients The International Society for Stem Cell Research Releases New ... |
 TheMedGuru | Extended Drug Therapy for Hepatitis Is Challenged New York Times, United States - “This is a treatment that should not be done,” said Dr. Howard Worman, professor of medicine at Columbia University College of Physicians and Surgeons, ... Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose ... Treatment for advanced hepatitis C doesn't work, researchers find Hepatitis C Therapy Useless for Some |
Resources
-
Sorry Currently Unavailable